Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Sotera Health is an attractive investment with strong potential for growth due to its essential services in the healthcare industry and reaffirmed financial guidance for 2026. Despite ongoing legal issues, the company appears to have a stable financial profile and expects increased profitability in the future through investments and improved pricing. The Sterigenics business, which generates the majority of revenue, has potential for margin expansion, while the Nelson Labs business is expected to see growth opportunities with new investments and regulations.

Bears say

Sotera Health is facing significant headwinds due to ongoing litigation regarding potential health risks associated with exposure to ethylene oxide (EO) in its sterilization facilities. This has resulted in a decline in its stock price and could continue to negatively impact the company's margins and distract management from pursuing growth opportunities. Additionally, the company's high debt levels could limit its ability to expand and compete in adjacent markets, and its attractive financial profile may be at risk due to potential future litigation settlements and expenses. These factors contribute to a negative outlook on Sotera's stock.

Sotera Health (SHC) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 6 analysts, Sotera Health (SHC) has a Buy consensus rating as of May 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.